Engineers Gate Manager’s Atossa Therapeutics ATOS Stock Holding History

Engineers Gate Manager’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,054	Closed	-$97K	–	1844
2021 Q4	$97K	Buy	+4,054	New	+$148K	﹤0.01%	1813

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Engineers Gate Manager's ATOS Position: Q1 2022 in Review

Engineers Gate Manager sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 4,054 shares — an estimated $97K sold.

Engineers Gate Manager first reported a position in ATOS in Q4 2021 and held it in 1 quarter. The position peaked at $97K in Q4 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

Engineers Gate Manager reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
Engineers Gate Manager sold 4,054 Atossa Therapeutics shares in Q1 2022, an estimated $97K.
Engineers Gate Manager first reported a position in Atossa Therapeutics in Q4 2021 and held it in 1 quarter.
Engineers Gate Manager's Atossa Therapeutics position peaked at $97K in Q4 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.